Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTIS2023-510456-23-00
CTIS2023-510456-23-00Active, not recruitingPhase 1

CBR-CMR316-3001

The Scripps Research Institute0 sites106 target enrollmentStarted: January 17, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
106
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 65+ (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Similar Trials

Active, not recruiting
Phase 1
A Phase 1b study of inhaled RCT1100 in Adults with Primary Ciliary Dyskinesia Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary ClearanceAdults with Primary Ciliary DyskinesiaMedDRA version: 20.0Level: PTClassification code: 10069713Term: Primary ciliary dyskinesia Class: 100000004850
CTIS2023-510521-14-00Recode Therapeutics Inc.12
Active, not recruiting
Phase 1
Assessment of narrowing of blood vessels after single application of two clascoterone formulations (cream and solution) onto the skin in comparison to three marketed topical corticosteroidsTest of vasocontriction properties for classification of topical steroid potencyMedDRA version: 20.0Level: LLTClassification code: 10047140Term: Vasoconstriction peripheral Class: 10047065
CTIS2023-507241-28-00Cassiopea S.p.A.33
Active, not recruiting
Phase 1
A study in healthy men to test how BI 764198 is processed in the bodyMedDRA version: 21.0Level: LLTClassification code: 10053349Term: Pharmacokinetic study Class: 10022891Healthy
CTIS2022-502327-22-00Boehringer Ingelheim International GmbH16
Recruiting
Phase 1
Individualization of dosage regimens in obese patients: application to acyclovirobesity
CTIS2022-500879-31-00Centre Hospitalier Universitaire De Toulouse20
Active, not recruiting
Phase 1
MK-1403 Single Dose Formulation PK StudyMedDRA version: 20.0Level: LLTClassification code: 10003601Term: Atherosclerosis Class: 10047065Atherosclerosis
CTIS2023-507984-20-00Merck Sharp & Dohme LLC16